There is also an interest comparison between the recently reported Annamycin trial (10 July 2024) with our Bisantrene trial at Sheba (6 November 2023).
What wasn't reported in the Annamycin trial press release (https://moleculin.com/moleculin-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml/) was that the median number of previous lines of treatment were 2, and for the cohort involving 3 to 7 lines of treatment the CR/OR rate was 14%.
This can be compared to our Sheba trial announcement (https://announcements.raceoncology.com/announcements/5414581) where for 15 patients with 3 to 9 lines of treatment (median = 4), Bisantrene achieved a CR rate of 33% and OR of 40%.
Conclusion: Annamycin is not good enough to treat hard to treat patients / what could Bistanrene do with 1st or 2nd line patients
Cardioprotection thread, page-650
-
- There are more pages in this discussion • 257 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |